Advertisement

U.S. Markets open in 3 hrs 3 mins

S&P Futures
5,880.25
-12.25(-0.21%)
Dow Futures
42,976.00
-193.00(-0.45%)
Nasdaq Futures
20,472.75
-69.25(-0.34%)
Russell 2000 Futures
2,239.80
-6.40(-0.28%)
Crude Oil
70.76
-0.98(-1.37%)
Gold
2,765.40
+5.60(+0.20%)

Kymera Therapeutics, Inc. (KYMR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

48.37

+1.81

(+3.89%)

At close: 04:00PM EDT

46.23

-2.14

(-4.42%)

After hours:

07:52PM EDT

Trade prices are not sourced from all markets

All

Zacks
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
GlobeNewswire
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the clearance of its Investigational